Genmab | GEN - Operating Expenses


Genmab reported DKK798M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Almirall EUR 531.16M 13.76M Jun/2026
Amarin USD 51.48M 113K Dec/2025
Amgen USD 4.78B 1.12B Mar/2026
argenx SE USD 1.02B 118M Jun/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
Bayer EUR 9.88B 452M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Demant DKK 9.63B 241M Dec/2025
Exelixis USD 359.47M 3.28M Mar/2026
Fresenius Medical Care EUR 4.34B 63M Mar/2026
Genmab DKK 798M 235M Dec/2025
GlaxoSmithKline GBP 5.8B 468M Jun/2026
GN Store Nord DKK 2.16B 1.94B Mar/2026
GRIFOLS EUR 1.55B 94M Jun/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Insmed USD 506.24M 7.31M Mar/2026
Lakefront Biotherapeutics EUR 70.18M 50.08M Mar/2026
Lonza CHF 2.9B 184M Jun/2025
Merck EUR 4.09B 687M Mar/2026
Novartis USD 10.2B 912M Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sanofi EUR 9.92B 607M Jun/2026
UCB EUR 2.96B 196M Dec/2025